Orthofix Medical (OFIX) Upgraded to B- by TheStreet
Other research analysts have also recently issued research reports about the stock. BidaskClub cut shares of Orthofix Medical from a strong-buy rating to a buy rating in a research report on Tuesday, July 31st. Zacks Investment Research raised shares of Orthofix Medical from a strong sell rating to a hold rating in a research report on Wednesday, July 4th. Finally, Cantor Fitzgerald boosted their price target on shares of Orthofix Medical to $66.00 and gave the company an overweight rating in a research report on Tuesday, August 7th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $62.25.
Shares of OFIX opened at $53.64 on Monday. Orthofix Medical has a 52-week low of $47.16 and a 52-week high of $61.98. The firm has a market cap of $994.09 million, a price-to-earnings ratio of 32.94, a price-to-earnings-growth ratio of 3.25 and a beta of 0.33.
In other Orthofix Medical news, insider Davide Bianchi sold 14,762 shares of the company’s stock in a transaction dated Tuesday, June 19th. The shares were sold at an average price of $60.00, for a total value of $885,720.00. Following the transaction, the insider now owns 41,260 shares of the company’s stock, valued at $2,475,600. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Brad Mason sold 2,500 shares of the company’s stock in a transaction dated Tuesday, July 10th. The shares were sold at an average price of $58.62, for a total transaction of $146,550.00. Following the completion of the transaction, the chief executive officer now directly owns 134,290 shares in the company, valued at approximately $7,872,079.80. The disclosure for this sale can be found here. In the last three months, insiders have sold 33,512 shares of company stock worth $1,939,470. Corporate insiders own 5.60% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC acquired a new position in Orthofix Medical in the first quarter valued at about $151,000. Quantbot Technologies LP acquired a new position in Orthofix Medical in the first quarter valued at about $161,000. Itau Unibanco Holding S.A. acquired a new position in Orthofix Medical in the second quarter valued at about $224,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in Orthofix Medical in the second quarter valued at about $227,000. Finally, Suntrust Banks Inc. acquired a new position in Orthofix Medical in the first quarter valued at about $256,000. 93.48% of the stock is currently owned by institutional investors.
About Orthofix Medical
Orthofix Medical Inc, a medical device company, provides musculoskeletal healing products and value-added services worldwide. It operates through four segments: BioStim, Extremity Fixation, Spine Fixation, and Biologics. The BioStim segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion and are indicated as treatment to enhance fusion success rates in cervical and lumbar spine, as well as a therapeutic treatment for non-spine fractures.
Receive News & Ratings for Orthofix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix Medical and related companies with MarketBeat.com's FREE daily email newsletter.